BUSINESS WIRE: Hummingbird Diagnostics to Present Poster on miLung Small RNA-Based Blood Test at the ASCO 2023 Annual Meeting
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.
HEIDELBERG, Germany --(BUSINESS WIRE)-- 31.05.2023 --
Hummingbird Diagnostics GmbH, a leader in reading blood-based small RNAs for early disease detection and characterization, today announced a poster presentation at the American Society for Clinical Oncology (ASCO) 2023 Annual Meeting on the miLung small RNA blood test for early-stage lung cancer detection.
Details of the poster presentation are as follows:
Title: Early detection of lung cancer using small RNAs
Presenting Author: Bruno Steinkraus, PhD, Chief Scientific Officer of Hummingbird Diagnostics
Session Title: Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology
Poster Board: #233
Location: Hall A
Date/Time: June 3, 2023 from 8:00 AM – 11:00 AM CDT
About Hummingbird Diagnostics GmbH
Hummingbird is harnessing the predictive power of blood-borne small RNAs to provide insights into human health and disease. Analyzing small RNAs with Hummingbird’s platform holds the potential for early disease detection, disease-specific prognostics, treatment response prediction, and the development of patient-centric therapies. To learn more, visit: https://www.hummingbird-diagnostics.com